Key result
Phenylbutazone markedly increased both phenprocoumon concentrations and prothrombin times, whereas sulfinpyrazone did not.
Why the study?
Does phenylbutazone or sulfinpyrazone alter the pharmacokinetics and pharmacodynamics of phenprocoumon in normal subjects?
Does phenylbutazone or sulfinpyrazone alter the pharmacokinetics and pharmacodynamics of phenprocoumon in normal subjects?
Phenylbutazone, but not sulfinpyrazone, significantly increases phenprocoumon concentrations and prothrombin times, indicating a clinically relevant drug interaction.
Phenylbutazone may potentiate phenprocoumon; leaves open clinical relevance and safety in anticoagulated patients.
To compare the marked hypoprothrombinemic augmentation in man of racemic warfarin sodium by the pyrazolons phenylbutazone and sulfinpyrazone with that of the coumarin anticoagulant phenprocoumon, these interactions were studied prospectively in six normal subjects. Large single doses of racemic phenprocoumon, 0.6 mg/kg orally, were administered with and without daily phenylbutazone, 300 mg, or sulfinpyrazone, 400 mg, beginning three days before phenprocoumon and continuing for 14 days. Daily blood samples were drawn for phenprocoumon content and one-stage prothrombin time. Phenylbutazone markedly increased both the phenprocoumon concentrations and prothrombin times, whereas sulfinpyrazone did not.
No takes yet. Share an insight, caveat, or question.
Robert A. O’Reilly (1982) studied Healthy volunteers (n=6). Phenylbutazone or sulfinpyrazone vs. Phenprocoumon alone was evaluated on Phenprocoumon concentrations and one-stage prothrombin time. Phenylbutazone markedly increased both phenprocoumon concentrations and prothrombin times, whereas sulfinpyrazone did not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: